XML 57 R36.htm IDEA: XBRL DOCUMENT v3.26.1
SEGMENT INFORMATION (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Information about Reportable Segments and Reconciliation of Segment Operating Income and Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Segment Net Sales
United States$1,003.5 $889.7 $1,941.1 $1,728.6 
Europe439.6 378.2 882.2 720.0 
Japan96.4 95.3 187.0 177.1 
Rest of World201.5 169.0 379.3 319.2 
Total segment net sales$1,741.0 $1,532.2 $3,389.6 $2,944.9 
Cost of Sales
United States$185.2 $167.5 $357.2 $313.5 
Europe93.4 84.8 187.0 167.0 
Japan15.3 13.6 29.6 25.9 
Rest of World55.2 43.9 102.8 83.7 
Total segment cost of sales$349.1 $309.8 $676.6 $590.1 
Selling, general, and administrative expenses
United States$164.7 $135.7 $318.8 $268.9 
Europe76.3 74.2 148.1 147.6 
Japan16.5 18.5 32.4 34.9 
Rest of World50.0 48.3 98.0 90.4 
Total segment selling, general, and administrative expenses$307.5 $276.7 $597.3 $541.8 
Other Segment Items
United States$0.7 $0.6 $1.5 $1.2 
Europe38.1 15.2 80.0 6.9 
Japan(8.9)(0.2)(14.9)(4.8)
Rest of World(7.1)(7.9)(14.6)(17.1)
Total other segment items (a)
$22.8 $7.7 $52.0 $(13.8)
Segment Operating Income
United States$652.9 $585.9 $1,263.6 $1,145.0 
Europe231.8 204.0 467.1 398.5 
Japan73.5 63.4 139.9 121.1 
Rest of World103.4 84.7 193.1 162.2 
Total segment operating income$1,061.6 $938.0 $2,063.7 $1,826.8 
_______________________________________________________________________________
(a)    Other segment items include research and development expenses and foreign currency.
The table below presents a reconciliation of segment operating income to consolidated pre-tax income (in millions):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Pre-tax Income Reconciliation
Segment operating income$1,061.6 $938.0 $2,063.7 $1,826.8 
Unallocated amounts:
Corporate items(538.3)(505.2)(1,033.1)(991.4)
Separation costs
— (4.2)— (8.4)
Certain litigation expenses(6.3)(15.5)(43.4)(26.4)
Foreign currency(3.8)(1.9)3.6 5.4 
Consolidated operating income513.2 411.2 990.8 806.0 
Non-operating income (expense)6.6 (11.0)(12.0)28.1 
Consolidated pre-tax income$519.8 $400.2 $978.8 $834.1 
Schedule of Enterprise-Wide Information
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Net Sales by Major Product Group
Transcatheter Aortic Valve Replacement$1,258.3 $1,130.9 $2,455.6 $2,177.5 
Transcatheter Mitral and Tricuspid Therapies198.6 134.5 373.7 249.7 
Surgical
284.1 266.8 560.3 517.7 
$1,741.0 $1,532.2 $3,389.6 $2,944.9